Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up

What Was Tested

This randomized controlled trial paper looks at Goserelin and Buserelin in the context of endometriosis.

To determine the long-term recurrence rate of endometriosis after treatment with gonadotropin-releasing hormone analogues (GnRH-a).

Patients no longer being followed in the gynecology clinic were sent a questionnaire to determine their state of health.

Who Took Part

The age groups tagged for this paper are teenagers, adults and middle-aged adults, women only.

Royal Free Hospital, London, a tertiary referral center for the treatment of endometriosis.

One hundred thirty patients with endometriosis had treatment with GnRH-a buserelin acetate, goserelin, and nafarelin acetate between the years 1985 and 1987.

How the Study Was Run

The design is described as randomized.

Because people in this Goserelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Information was also requested from the patient's general practitioner.

What Was Measured

PubMed files the paper under topics including Buserelin, Endometriosis, Goserelin, Nafarelin and Recurrence.

What This Means in Plain Language

The paper is a randomized study of Goserelin and Buserelin in people with endometriosis.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1993 (Fertility and sterility), a journal based in United States.

More context: the Goserelin compound page and the Buserelin compound page, Endometriosis research.